<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449956</url>
  </required_header>
  <id_info>
    <org_study_id>0507A-149</org_study_id>
    <secondary_id>MK0507A-149</secondary_id>
    <secondary_id>2007_011</secondary_id>
    <nct_id>NCT00449956</nct_id>
  </id_info>
  <brief_title>MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)</brief_title>
  <official_title>Multicenter, Double-Blind, Active Comparator-controlled Study to Evaluate the Safety and Efficacy of MK0507A in Patients With Glaucoma and Ocular Hypertension Who Are Inadequately Controlled on Beta-Blockers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The clinical study compares safety and efficacy of MK0507A (dorzolamide 1.0% / timolol 0.5%)
      with 1) timolol 0.5% and with 2) concomitant therapy with dorzolamide 1.0% / timolol 0.5% in
      patients with glaucoma and ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2007</start_date>
  <completion_date type="Actual">February 16, 2008</completion_date>
  <primary_completion_date type="Actual">February 16, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Intraocular Pressure (IOP) From Baseline at 8 Weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from baseline to 8 weeks in Intraocular Pressure (IOP) assessed 2 hours after ocular instillation (at Hour 2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Intraocular Pressure (IOP) at 8 Weeks</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Percent Change from baseline to 8 weeks in Intraocular Pressure (IOP) assessed 2 hours after ocular instillation (at Hour 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Outflow Pressure Reduction Rate at 8 Weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent Change from baseline to 8 weeks in Outflow Pressure Reduction Rate assessed 2 hours after ocular instillation (at Hour 2)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">474</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination of dorzolamide hydrochloride and timolol maleate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concomitant use of dorzolamide hydrochloride and timolol maleate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>timolol maleate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dorzolamide hydrochloride (+) timolol maleate</intervention_name>
    <description>Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: timolol maleate</intervention_name>
    <description>timolol maleate 0.5%, 8-week</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: dorzolamide hydrochloride</intervention_name>
    <description>dorzolamide hydrochloride 1%, 8-week</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with glaucoma and ocular hypertension

        Exclusion Criteria:

          -  History of ocular surgery within 3 months

          -  Administration contradiction to timolol and dorzolamide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Kitazawa Y, Araie M; Research Group on MK-0507A. [Double-masked, phase III comparative study of the combination ophthalmic solution of the 1% dorzolamide hydrochloride/0.5% timolol maleate (MK-0507A) in patients with glaucoma and ocular hypertension]. Nippon Ganka Gakkai Zasshi. 2011 Jun;115(6):495-507. Japanese.</citation>
    <PMID>21735753</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2007</study_first_submitted>
  <study_first_submitted_qc>March 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2007</study_first_posted>
  <results_first_submitted>January 23, 2009</results_first_submitted>
  <results_first_submitted_qc>April 6, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 29, 2009</results_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase III.
Studied period: April 9, 2007 (date study therapy started for the first subject) to February 16, 2008 (the last subjectâ€™s last visit stipulated in study protocol). Study was conducted at 67 clinical sites.</recruitment_details>
      <pre_assignment_details>Outpatients with primary open angle glaucoma (broad definition) and/or ocular hypertension received 4-week timolol 0.5% monotherapy in the wash-out period before the study randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)</title>
          <description>MK0507A (Dorzolamide 1.0% / Timolol 0.5% combination), one drop per dose twice daily to the study eye.</description>
        </group>
        <group group_id="P2">
          <title>Timolol 0.5%</title>
          <description>Timolol 0.5%, one drop per dose twice daily to the study eye.</description>
        </group>
        <group group_id="P3">
          <title>Concomitant (Dorzolamide 1.0% / Timolol 0.5%)</title>
          <description>Concomitant (Dorzolamide 1.0%, one drop per dose three times daily to the study eye / Timolol 0.5%, one drop per dose twice daily to the study eye).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="193"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)</title>
          <description>MK0507A (Dorzolamide 1.0% / Timolol 0.5% combination), one drop per dose twice daily to the study eye.</description>
        </group>
        <group group_id="B2">
          <title>Timolol 0.5%</title>
          <description>Timolol 0.5%, one drop per dose twice daily to the study eye.</description>
        </group>
        <group group_id="B3">
          <title>Concomitant (Dorzolamide 1.0% / Timolol 0.5%)</title>
          <description>Concomitant (Dorzolamide 1.0%, one drop per dose three times daily to the study eye / Timolol 0.5%, one drop per dose twice daily to the study eye).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="189"/>
            <count group_id="B2" value="92"/>
            <count group_id="B3" value="193"/>
            <count group_id="B4" value="474"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="10.8"/>
                    <measurement group_id="B2" value="61.3" spread="11.6"/>
                    <measurement group_id="B3" value="62.3" spread="12.7"/>
                    <measurement group_id="B4" value="62.4" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="245"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Open-angle glaucoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal-tension glaucoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ocular hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraocular pressure (IOP) at Hour 2</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.54" spread="2.07"/>
                    <measurement group_id="B2" value="20.23" spread="1.85"/>
                    <measurement group_id="B3" value="20.38" spread="2.31"/>
                    <measurement group_id="B4" value="20.42" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Intraocular Pressure (IOP) From Baseline at 8 Weeks</title>
        <description>Change from baseline to 8 weeks in Intraocular Pressure (IOP) assessed 2 hours after ocular instillation (at Hour 2)</description>
        <time_frame>8 weeks</time_frame>
        <population>Last observed value during the 8-week treatment period was used in the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)</title>
            <description>MK0507A (Dorzolamide 1.0% / Timolol 0.5% combination), one drop per dose twice daily to the study eye.</description>
          </group>
          <group group_id="O2">
            <title>Timolol 0.5%</title>
            <description>Timolol 0.5%, one drop per dose twice daily to the study eye.</description>
          </group>
          <group group_id="O3">
            <title>Concomitant (Dorzolamide 1.0% / Timolol 0.5%)</title>
            <description>Concomitant (Dorzolamide 1.0%, one drop per dose three times daily to the study eye / Timolol 0.5%, one drop per dose twice daily to the study eye).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Intraocular Pressure (IOP) From Baseline at 8 Weeks</title>
          <description>Change from baseline to 8 weeks in Intraocular Pressure (IOP) assessed 2 hours after ocular instillation (at Hour 2)</description>
          <population>Last observed value during the 8-week treatment period was used in the Full Analysis Set (FAS).</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.50" lower_limit="-2.86" upper_limit="-2.15"/>
                    <measurement group_id="O2" value="-1.82" lower_limit="-2.33" upper_limit="-1.31"/>
                    <measurement group_id="O3" value="-2.78" lower_limit="-3.13" upper_limit="-2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.30</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
            <estimate_desc>An analysis of covariance model with a factor for treatment and time-matched baseline as a covariate was used to compute 95% confidence intervals.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin = 1.2 mmHg</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
            <estimate_desc>An analysis of covariance model with a factor for treatment and time-matched baseline as a covariate was used to compute 95% confidence intervals.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Intraocular Pressure (IOP) at 8 Weeks</title>
        <description>Percent Change from baseline to 8 weeks in Intraocular Pressure (IOP) assessed 2 hours after ocular instillation (at Hour 2)</description>
        <time_frame>8 Weeks</time_frame>
        <population>Last observed value during the 8-week treatment period was used in the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)</title>
            <description>MK0507A (Dorzolamide 1.0% / Timolol 0.5% combination), one drop per dose twice daily to the study eye.</description>
          </group>
          <group group_id="O2">
            <title>Timolol 0.5%</title>
            <description>Timolol 0.5%, one drop per dose twice daily to the study eye.</description>
          </group>
          <group group_id="O3">
            <title>Concomitant (Dorzolamide 1.0% / Timolol 0.5%)</title>
            <description>Concomitant (Dorzolamide 1.0%, one drop per dose three times daily to the study eye / Timolol 0.5%, one drop per dose twice daily to the study eye).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Intraocular Pressure (IOP) at 8 Weeks</title>
          <description>Percent Change from baseline to 8 weeks in Intraocular Pressure (IOP) assessed 2 hours after ocular instillation (at Hour 2)</description>
          <population>Last observed value during the 8-week treatment period was used in the FAS.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.99" lower_limit="-13.69" upper_limit="-10.28"/>
                    <measurement group_id="O2" value="-8.74" lower_limit="-11.18" upper_limit="-6.30"/>
                    <measurement group_id="O3" value="-13.46" lower_limit="-15.15" upper_limit="-11.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Outflow Pressure Reduction Rate at 8 Weeks</title>
        <description>Percent Change from baseline to 8 weeks in Outflow Pressure Reduction Rate assessed 2 hours after ocular instillation (at Hour 2)</description>
        <time_frame>8 weeks</time_frame>
        <population>Last observed value during the 8-week treatment period was used in the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)</title>
            <description>MK0507A (Dorzolamide 1.0% / Timolol 0.5% combination), one drop per dose twice daily to the study eye.</description>
          </group>
          <group group_id="O2">
            <title>Timolol 0.5%</title>
            <description>Timolol 0.5%, one drop per dose twice daily to the study eye.</description>
          </group>
          <group group_id="O3">
            <title>Concomitant (Dorzolamide 1.0% / Timolol 0.5%)</title>
            <description>Concomitant (Dorzolamide 1.0%, one drop per dose three times daily to the study eye / Timolol 0.5%, one drop per dose twice daily to the study eye).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Outflow Pressure Reduction Rate at 8 Weeks</title>
          <description>Percent Change from baseline to 8 weeks in Outflow Pressure Reduction Rate assessed 2 hours after ocular instillation (at Hour 2)</description>
          <population>Last observed value during the 8-week treatment period was used in the FAS.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.47" lower_limit="20.07" upper_limit="26.88"/>
                    <measurement group_id="O2" value="17.17" lower_limit="12.29" upper_limit="22.05"/>
                    <measurement group_id="O3" value="26.75" lower_limit="23.37" upper_limit="30.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)</title>
          <description>MK0507A (Dorzolamide 1.0% / Timolol 0.5% combination), one drop per dose twice daily to the study eye.</description>
        </group>
        <group group_id="E2">
          <title>Timolol 0.5%</title>
          <description>Timolol 0.5%, one drop per dose twice daily to the study eye.</description>
        </group>
        <group group_id="E3">
          <title>Concomitant (Dorzolamide 1.0% / Timolol 0.5%)</title>
          <description>Concomitant (Dorzolamide 1.0%, one drop per dose three times daily to the study eye / Timolol 0.5%, one drop per dose twice daily to the study eye).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2"/>
                <counts group_id="E2" subjects_affected="1"/>
                <counts group_id="E3" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36"/>
                <counts group_id="E2" subjects_affected="12"/>
                <counts group_id="E3" subjects_affected="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Corneal epithelium defect</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site irritation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

